Physiologically based pharmacokinetic‐pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics

Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease

(2019) Jessica Breton et al.   INFLAMMATORY BOWEL DISEASES

Physiologically-based pharmacokinetics of ziprasidone in pregnant women

(2019) Carla Biesdorf et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacodynamic attainment of the synergism of meropenem and fosfomycin combination against Pseudomonas aeruginosa producing metallo-β-lactamase

(2019) James Albiero et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant Acinetobacter baumannii Using Checkerboard Information

(2019) Thatiany Cevallos Menegucci et al.   Microbial Drug Resistance

Learning and augmenting natural processes: potential means of combating antimicrobial resistance from a drug R&D perspective

(2019) Charles Oo et al.   DRUG DISCOVERY TODAY

Pediatric Dose Selection and Utility of PBPK in Determining Dose

(2018) Ian E. Templeton et al.   AAPS Journal

Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants (PROOF)

(2018) E Wenzler et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment

(2018) Christopher M. Rubino et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation

(2018) Thomas M. Polasek et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The combination of fosfomycin plus meropenem is synergistic for Pseudomonas aeruginosa PA01 in a Hollow Fiber Infection Model (HFIM).

(2018) G.L. Drusano et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A model-based analysis of pharmacokinetic–pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa

(2018) S.K.B. Sy et al.   CLINICAL MICROBIOLOGY AND INFECTION

Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity

(2017) Justin R. Lenhard et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Conventional Versus Prolonged Infusion of Meropenem in Neonates With Gram-negative Late-onset Sepsis

(2017) Abd Elazeez Shabaan et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae

(2016) James Albiero et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections

(2016) Juan José Castón et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy

(2015) Angela Colbers et al.   CLINICAL PHARMACOKINETICS

Effect of reducing the paediatric stavudine dose by half: A physiologically-based pharmacokinetic model

(2015) Sherwin K.B. Sy et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Sepsis caused by New Delhi metallo-β-lactamase (blaNDM-1) and qnrD-producing Morganella morganii, treated successfully with fosfomycin and meropenem: case report and literature review

(2015) Verónica Seija et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Predicting Pediatric Age-Matched Weight and Body Mass Index

(2014) Sherwin K. B. Sy et al.   AAPS Journal

Pharmacokinetics ofpara-Aminosalicylic Acid in HIV-Uninfected and HIV-Coinfected Tuberculosis Patients Receiving Antiretroviral Therapy, Managed for Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis

(2014) Lizanne de Kock et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Dosing in Children: A Critical Review of the Pharmacokinetic Allometric Scaling and Modelling Approaches in Paediatric Drug Development and Clinical Settings

(2014) Iftekhar Mahmood   CLINICAL PHARMACOKINETICS

Successful Treatment of a Patient with Ventriculoperitoneal Shunt-Associated Meningitis Caused by Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae

(2014) Yu-Chen Tseng et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Estimation of Intracellular Concentration of Stavudine Triphosphate in HIV-Infected Children Given a Reduced Dose of 0.5 Milligrams per Kilogram Twice Daily

(2013) Sherwin K. B. Sy et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Serotypes and Patterns of Antibiotic Resistance in Strains Causing Invasive Pneumococcal Disease in Children Less than 5 Years of Age

(2013) Chunfeng Liu et al.   PLoS One

Safety and Effectiveness of Meropenem in Infants With Suspected or Complicated Intra-abdominal Infections

(2012) M. Cohen-Wolkowiez et al.   CLINICAL INFECTIOUS DISEASES

An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry

(2012) Sieto Bosgra et al.   CRITICAL REVIEWS IN TOXICOLOGY

Optimal Dosage Regimen of Meropenem for Pediatric Patients Based on Pharmacokinetic/Pharmacodynamic Considerations

(2011) Yuka Ohata et al.   Drug Metabolism and Pharmacokinetics

Combination Antibiotic Therapy for Empiric and Definitive Treatment of Gram-Negative Infections: Insights from the Society of Infectious Diseases Pharmacists

(2011) Natalie Boyd et al.   PHARMACOTHERAPY

Pharmacokinetic and Pharmacodynamic Properties of Meropenem

(2008) David P. Nicolau   CLINICAL INFECTIOUS DISEASES

Use of a clinically derived exposure–response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints

(2008) Paul G. Ambrose et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE